Would you consider another EGFR-directed therapy in this patient, and does her mutational status affect your decision?
CASE: Metastatic Colorectal Cancer (Part 2)
Following her first-line recurrence, Diane is switched to FOLFIRI, and bevacizumab is continued.
In July of 2014, she presents to her oncologist with fatigue, dyspnea, and worsening performance status, and her CEA had increased to 180 ng/mL.
Based on results of her mutational analysis, which showed KRAS WT; BRAF negative; RAS WT, the patient is considered eligible for treatment with an anti-EGFR agent, and she is initiated on cetuximab + irinotecan.
In November of 2014, the patient presents with dyspnea, increasing CEA and worsening performance status.
Sotorasib/Panitumumab Combo Improves PFS in Refractory KRAS G12C+ mCRC
October 23rd 2023The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
T-IELs Could Hold the Key for CRC Immunotherapy
October 10th 2023Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
Read More
CAPOX Regimen Appears Noninferior to FOLFOX in CRC
October 8th 2023The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
Read More